Introduction
Vaccines are one of the most costeffective public health measures.' But while their benefits far outweigh their risks and costs, no vaccine is perfectly safe. Vaccine safety is initially assessed in prelicensure clinical trials. However, such trials usually have sample sizes that are insufficient to detect rare adverse events. In addition, vaccine trials are usually carried out in well-defined, homogeneous populations with relatively short follow-up periods, which may limit their generalizability. Postlicensure drug evaluations have relied on passive surveillance systems to monitor adverse events. Such systems are more practical and less expensive than controlled trials; however, their data are usually inadequate to determine causality. 2 Passive surveillance systems for vaccine adverse events have been useful for evaluating contraindications to the diphtheria-tetanus-pertussis (DTP) vaccine3 and for assessing the safety of simultaneous or combined vaccinations.4 Reporting sensitivities allow the utility of such systems for detecting and analyzing rare adverse events to be evaluated. In Adverse Event Reporting System from November 1990 to December 1993. The number of reports for selected outcomes and the estimated number of vaccine doses administered are shown in Table 1 .
Reporting sensitivities of various outcomes are shown in Table 2 . Sensitivities ranged from 72% for poliomyelitis after the oral poliovirus vaccinc to less than 1 % for rash and thrombocytopenia after the MMR vaccine. Reporting sensitivity of the reporting system overall was lower than that of the monitoring system for all vaccine-outcome combinations except seizures after MMR and thrombocytopenia after MMR, but reporting sensitivity of the reporting system when analyzed by vaccines administcred in the public sector only was greater than that of the system overall for all outcomes except thrombocytopenia.
Discussion
The utility of passive surveillance has several potential limitations. For example, underreporting is often a problem, limiting the system's ability to detect new or rare events.'" Clinical information obtained on report forms is often inadequate for assessment, and reports may be biased to prevailing concepts of adverse events and changing publicity.2'2' An increasc in reported events may be owing to an increase in the number of doses of vaccine administered, information that may not be readily available.
Reporting of adverse events appears to depend on a number of factors, such as clinical seriousness, temporal proximity to vaccination, and health care workers' awareness of and obligation to report particular adverse events. 
